Intratumoral Sotigalimab with Pembrolizumab Activates Antigen Presenting cells and Induces Local and Distant Anti Tumor Responses in First line Metastatic Melanoma: Results of a Phase I/II Study By lsc-webmaster Intratumoral Sotigalimab with Pembrolizumab Activates Antigen Presenting cells and Induces Local and Distant Anti Tumor Responses in First line Metastatic Melanoma: Results of a Phase I/II Study Read More »
Distinct Biosignatures Associate with Survival After Chemoimmunotherapy in a Randomized, Three-arm Phase II Study in Patients with Metastatic Pancreatic Cancer By lsc-webmaster Distinct Biosignatures Associate with Survival After Chemoimmunotherapy in a Randomized, Three-arm Phase II Study in Patients with Metastatic Pancreatic Cancer Read More »
Intratumoral CD40 Agonist Sotigalimab (APX005M) with Pembrolizumab Induces Broad Innate and Adaptive Immune Activation in Local and Distant Tumors in Metastatic Melanoma By lsc-webmaster Intratumoral CD40 Agonist Sotigalimab (APX005M) with Pembrolizumab Induces Broad Innate and Adaptive Immune Activation in Local and Distant Tumors in Metastatic Melanoma Read More »
First in Pediatrics Phase 1 Study Of CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors By lsc-webmaster First in Pediatrics Phase 1 Study Of CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors Read More »
A Phase 1b Study of CD40 Agonistic Monoclonal Antibody APX005M Together with Gemcitabine and nab-Paclitaxel with or without Nivolumab in Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Patients By lsc-webmaster A Phase 1b Study of CD40 Agonistic Monoclonal Antibody APX005M Together with Gemcitabine and nab-Paclitaxel with or without Nivolumab in Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Patients Read More »
First in Human Study with the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors By lsc-webmaster First in Human Study with the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors Read More »